MedTrace Logo

Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers(Fed)

NCT03927170 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2020-07-23

No results posted yet for this study

Summary

Crossover study to compare the pharmacokinetic characteristics of GLH1SM sustained release tablet and Janumet XR tablet in fed condition

Conditions

  • Healthy

Interventions

COMBINATION_PRODUCT

Janumet XR tablet 100/1000 mg

To administrate the Janumet XR tablet

COMBINATION_PRODUCT

GLH1SM tablet 100/1000 mg

To administrate the GLH1SM tablet

Sponsors & Collaborators

  • GL Pharm Tech Corporation

    lead INDUSTRY

Principal Investigators

  • Kyungho Jang, MD, Ph.D · Chonbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-02
Primary Completion
2019-09-11
Completion
2019-10-23

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03927170 on ClinicalTrials.gov